A new publication tied to growth hormone-releasing hormone research was listed on October 1, 2026. The paper, titled "Cardiomyocyte-specific expression of HIF-1a mediates the cardioprotective effects of growth hormone-releasing hormone," appeared in the American Journal of Physiology, Heart and Circulatory Physiology.
Sermorelin is a synthetic analog of growth hormone-releasing hormone and remains classified as unapproved for research use. The publication is indexed under PubMed ID 42541513.
This brief reports only the existence and bibliographic details of the publication. No specific findings, data, or conclusions from the study are described here, as that information was not provided. Readers interested in the underlying mechanisms discussed in the paper should consult the original article directly through the linked source.
For general background on sermorelin, including its classification and research status, see the compound overview.